Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Finland

Marie Skłodowska-Curie Action · Running

MarkovForScreening Risk-Stratified and Personalized Cancer Screening with Bidirectional Multistate Markov Models

Coordinator
Tampereen Korkeakoulusaatio Sr, Finland
Runs
1 July 2026 to 30 June 2028
Status
Running
EU funding
€242k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101278807

What the project is doing

In the project's own words, from its summary on CORDIS.

Multistate Markov Models (MMM) are powerful tools for analyzing the progression of diseases through different stages, particularly in oncology. Recent studies have modeled stage transition probabilities as functions of multimodal, time-dependent biomarkers to enable predictions based on histopathological features. However, current MMM approaches often overlook the reverse relationship—that is, the influence of the disease stage on the evolution of time-dependent biomarkers.

At worst, this omission leads to misspecification bias, at best we miss the opportunity of a better modeling. In this proposal, I aim to address this gap by developing MMM methodologies that explicitly account for the bidirectional relationship between stage progression and associated time-dependent covariates, I call them bidirectional-MMM (bi-MMM). This research is particularly relevant in cancer screening contexts, where a patient's cancer stage influences treatment decisions and, consequently, the trajectory of their biomarkers, which might be high-dimensional and missing at random.

A more accurate representation of cancer progression enables the design of personalized screening protocols, thereby improving the harm-to-benefit ratio and reducing the risk of overdiagnosis –when a patient is heavily treated for a cancer that would not have caused symptoms or harm during their lifetime. Overdiagnosis is particularly prevalent in prostate cancer screening compared to other cancer screening programs, even though prostate cancer is the most common cancer among men in Western countries.

The supervisors of this project, Prof. Auvinen and Prof. Nevalainen, are currently leading an innovative prostate cancer screening initiative at Tampere University, in alignment with European health policy goals. This initiative is the primary motivation and data source for the project. A secondment in France is also planned with Prof. Proust-Lima, a leading expert in MMM, to enhance the project's impact.

Topics

Who is involved

OrganisationCityCountryRole
Tampereen Korkeakoulusaatio SrTampereFinlandCoordinator
Universite De BordeauxBordeauxFranceAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI